Kornimate/medical-research-clean huggingface dataset:
rosuvastatin orbital germany

Conditions: Hypercholesterolemia

Summary: the primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related costs during the 36 month.


Eligibility criteria:
inclusion criteria: * high cholesterol with an indication for cholesterol-lowering medication (statins) exclusion criteria: * contra-indications for statin therapy

Keywords: hypercholesterolemia statin compliance
actions & insights evaluating a novel diabetes management solution

Conditions: Diabetes Mellitus ( Type 1 and Type 2)

Summary: single visit outcome study to obtain qualitative and quantitative data for a new bgms.

during ascend, patients will complete a single visit clinical study divided into two distinct parts. part 1 involves each subject completing a number of simple quantitative exercises to gauge their level of comprehension of diabetes related information. subjects will then continue during the same visit to complete part 2 which involves gathering qualitative feedback from each subject on the new blood glucose monitoring system.

Eligibility criteria:
summary off: inclusion criteria: * diagnosed with t1dm or t2dm * performs smbg * male or female, at least 16 years old. * able to communicate (speak, read and write) in english * willing to sign an informed consent. exclusion criteria: * unlikely to be compliant with the study in the opinion of study staff. * conflict of interest - prospective participants are currently working for, previously worked for, or have an immediate family member currently working for a company that manufactures or markets the products tested under this procedure
validation of downloadable mobile snore applications by polysomnography (psg)

Conditions: Apnea, Obstructive; Snoring

Summary: the aim of this study is to validate the downloadable mobile snore applications by polysomnography.

obstructive sleep apnea(osa) is characterized by multiple episodes of upper airway collapse during sleep and considered as a major health issue worldwide due to comorbidity with obesity, hypertension, diabetes and more advanced cardiovascular diseases. the noisy sounds of snoring caused by osa bother bed partner sleepless and lead to long-term health problems. mobile snore applications are convenient and accessible for patients to monitor the progress of osa by themselves, but there are no reliable psg-validated applications.

Eligibility criteria:
inclusion criteria: * willing to sign inform consent with aged more than 20 years old * mild to moderate osa, ahi (apnea-hypopnea index) \< 30 exclusion criteria: * significant lung disease * skeletal facial framework problems * central apnea * receiving acupuncture in recent 2 weeks * taking hypnotic drugs

Keywords: obstructive sleep apnea polysomnography smart phone application
evaluation of the cone outer segment tips line after epiretinal membrane surgery

Conditions: Epiretinal Membrane

Summary: the recovery of the cone outer segment tips (cost) line after epiretinal membrane (erm) surgery using spectral-domain optical coherence tomography (sd-oct) was assessed.

epiretinal membrane (erm) may cause decreased central vision or metamorphopsia. pars plana vitrectomy with membrane peeling has become the standard treatment for epiretinal membrane. however, visual recovery or symptomatic relief is not always satisfactory in all eyes despite successful membrane removal. spectral domain optical coherence tomography (sd-oct) is a non-invasive imaging device for various vitreoretinal diseases. cone outer segment tips (cost) line is a line observed between is/os line and rpe in sd-oct. the investigators examined the correlation of visual acuity and the recovery of photoreceptor layer after erm surgery, taking cost line into account as a new parameter

Eligibility criteria:
inclusion criteria: * patients who received epiretinal membrane surgery between june, 2008, and november, 2010, at kyorin eye center. * only eyes with postoperative follow-up period more than 6 months were included. exclusion criteria: * eyes with secondary epiretinal membrane (previous history of uveitis, intraocular surgery, pre-operatively noted retinal breaks, etc.) were excluded.

Keywords: cone outer segment tips line inner segment/outer segment junction line optical coherence tomography epiretinal membrane
comparison of spinal kinematics between asymptomatic subjects and patients with low back pain

Conditions: Low Back Pain

Summary: low back pain (lbp) is a complex and common problem with major societal repercussions. clinical evaluations, and especially functional assessments, are necessary for proper diagnosis and decisions on the most appropriate treatment. the assessment of lumbar kinematics has been frequently described. for instance, measures of range of motion (rom), angular velocities and acceleration of the total lumbar spine (tlx) have demonstrated some differences between healthy subjects and lbp patients. however, recent evidence has suggested that models evaluating the tlx are insufficient. in fact, regional differences in kinematics have been described between the upper lumbar spine and the lower lumbar spine. the aim of this study is to evaluate the differences in spinal kinematics between healthy subjects and lbp patients using a multi-segment model of the spine that allows regional analysis.

a case-controlled study will be performed to compare asymptomatics subjects and patients with low back pain. rom, angular velocities and coordination of the spine will be collected in a laboratory with a camera-based system (vicon). subjects will have to perform normal rom assessment in the three anatomical planes, as well as different functional activities such as sit to stand, step and walking. the measurement session will occur on one occasion for each participant.

Eligibility criteria:
inclusion criteria: * sufficient french level * bmi between 18 and 27 * non-specific low back pain for more than 3 months (pain provoked by movements, postures or activities) exclusion criteria: * pregnancy * spondylolisthesis * infection * rheumatological or neurological diseases * spinal fractures * known spinal deformation (scoliosis, ...) * back surgery * tumours * radicular symptoms (with neurological signs). pain irradiating in the lower limbs with decrease strength, sensitivity and reflex. * high level of pain (severity and irritability) at the time of experiment that prevents repeated movements. * other concomitant pain or condition that could compromise the evaluation of lumbar kinematics.

Keywords: spinal kinematics
clinical analysis of pain after hysterectomy

Conditions: Postoperative Pain

Summary: patients undergone either laparoscopic or vaginal hysterectomy will called for a clinical examination 1-3 years after surgery, if they suffer from pain 6 months after surgery. the aims of the study are: 1. to reveal whether the pain is postsurgical in nature, or if there are any other reasons for the pain. 2. to reveal the type of pain, neuropathic, nociceptive or idiopathic. 3. to reveal the impact of pain on quality of life.

patients undergone either laparoscopic or vaginal hysterectomy will called for a clinical examination 1-3 years after surgery, if they suffer from pain 6 months after surgery. all patients were treated in pirkanmaa district hospital and the anesthesia was either propofol-infusion or sevoflurane gas with remifentanil-infusion. 6months after the surgery, questionnaires about pelvic pain were sent to the patients. patients still having pain at that time, were invited for detailed sensory and gynecological examinations.

Eligibility criteria:
inclusion criteria: * hysterectomy 1-3 years previously * suffering from pain 6months postsurgically exclusion criteria: -

Keywords: chronic pain hysterectomy quality of life
cost- effectiveness and quality of life assessment in major depression disorder

Conditions: Depression

Summary: to evaluate the effectiveness of one algorithm for major depression disorder (mdd) using medications available in the brazilian public healthcare system (sus), and assessment of the quality of life of these patients. a randomized pragmatic trial was conducted. an algorithm was developed for the treatment of episodes of unipolar depression episodes.

the study design was that of a pragmatic randomized clinical trial to evaluate the effectiveness of treatments for mood disorders in a public healthcare context in the city of porto alegre, in southern brazil. the algorithm was originally developed for the treatment of major depression by a delphi panel of experts from psychiatric associations in brazil. all subjects provided an informed consent form, in writing, in order to participate in the study protocol, which was approved by the institutional ethics committee. procedures and measurements of the study the subjects under evaluation were selected and they followed the stages defined by the treatment protocol: 1. sample selection by being referred from the primary healthcare clinics in the municipality; 2. informative talk about mood disorders and the research, with the informed consent forms being provided to the subjects; 3. screening for unipolar depression episodes with the use of the patient health questionnaire (phq-9), and hypomanic symptoms checklist brazilian version (hcl -32-bv); 4. diagnostic evaluation through the mini international neuropsychiatric interview (mini) and clinical interview for individuals with positive results in the screening instruments; 5. baseline and demographic assessments using standardized semi-structured interviews in the first and second visits; 6. in each clinic visit, the severity of the symptoms were evealuated using the clinical global impression scale (cgi), hamilton rating scale for depression (hrsd), and young manic rating scale (ymrs); 7. biweekly follow-up, changed to monthly after stabilization - with a maximum follow-up period of 52 weeks.

Eligibility criteria:
inclusion criteria: 1. ages between 18 and 65; 2. current acute unipolar depression episode; 3. total capacity to understand and respond to self-applied instruments; 4. the presence of symptoms in the last 30 days; 5. abstinence for at least 30 days for drug addicts exclusion criteria: 1. presence of organic brain syndrome (obs); 2. pregnancy or lactation; 3. criteria for psychiatric hospitalization.

Keywords: cost effectiveness unipolar depression major depression disorder quality of life disorder
purpose of this study is to evaluate the safety and efficacy of one, two, or three istents for the reduction of intraocular pressure in open-angle glaucoma subjects

Conditions: Primary Open Angle Glaucoma (POAG)

Summary: the purpose of this study is to evaluate the safety and efficacy of the istent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.


Eligibility criteria:
inclusion criteria: * diagnosed with primary open-angle glaucoma (poag) * subject on two topical hypotensive medications exclusion criteria: * traumatic, uveitic, neovascular, or angle closure glaucoma * fellow eye already enrolled

Keywords: open angle glaucoma surgery glaucoma, open-angle ocular hypertension eye diseases
unity 2: a study of an investigational treatment regimen of dcv+asv+bms-791325 in a fixed dose combination (the dcv 3daa (direct acting antiviral) regimen) with or without rbv for 12 weeks for the treatment of chronic hepatitis c virus(hcv)genotype 1 infection in subjects with compensated cirrhosis

Conditions: Hepatitis C

Summary: to demonstrate the effectiveness of dcv 3daa fixed dose combination with or without ribavirin in treatment naive cirrhotic subjects.

masking is double blind for rbv: two or more parties are unaware of the intervention assignment.

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * subjects chronically infected with hcv genotype 1 * subjects with compensated cirrhosis * hcv rna ≥ 10,000 iu/ml at screening * treatment-naïve subjects with no previous exposure to an interferon formulation (ie, ifnα, pegifnα), ribavirin (rbv), or hcv direct acting antivirals (daa) (protease, polymerase inhibitor, etc.) * treatment-experienced subjects are eligible including exposure to anti-hcv agents of a mechanistic class other than those contained in the daclatasvir (dcv) / asunaprevir (asv) /bms-791325 triple regimen is permitted. examples of permitted agents include, but are not limited to nucleoside/nucleotide inhibitors of nonstructural protein 5b (ns5b) polymerase, inhibitors of cyclophilin, or inhibitors of microrna. exclusion criteria: * subjects without cirrhosis * liver or any other organ transplant * current or known history of cancer within 5 years prior to screening * documented or suspected hepatocellular carcinoma(hcc) * evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy
safety study of cancer specific epitope peptides cocktail for cervical, gi, and lung tumors

Conditions: Metastatic Tumors

Summary: the purpose of this study is to evaluate the clinical safety and efficacies of cyclophosphamide combined cancer specific epitope peptides cocktail for advanced/relapsed solid tumors including gi/lung/cervical cancers

koc1, ttk, co16(urlc10), depdc1, mphosph1 have been identified using genome-wide expression profile analysis by the use of cdna microarray in the previous studies. the investigators have determined the hla-a\*2402 restricted epitope peptides respectively derived from koc1, ttk, co16(urlc10), depdc1, and mphosph1 showed strong inf-gamma production when stimulated with the appropriate targets expressing the appropriate protein and hla-a\*2402. furthermore, when vaccinated these peptides, specific ctls were determined after the vaccination. therefore the investigators focused on the prevention of further expansion of the solid tumors highly expressing these 5 proteins using these 5 peptides.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of unresectable or relapsed gastrointestinal, lung or cervical cancer patients * performance status 0-1 * age between 20 and 80 * at least 4 weeks after previous therapy * life expectancy more than 3 months * permissible bone marrow, liver and renal function * hla-a2402 * no viral hepatitis, hiv or htlv1 exclusion criteria: * severe underlying disease * pregnant or lactating women * active brain metastasis * uncontrollable infection * under systemic corticosteroid or immune suppressant treatment * history of allergy to epitope peptides or ifa

Keywords: epitope peptide cyclophosphamide interleukin-2
stent versus conservative treatment in patients with deep venous obstruction

Conditions: Deep-Venous Thrombosis; Deep Venous Stenting; Randomized Clinical Trial

Summary: patients will be randomised between deep venous stenting or conservative management


Eligibility criteria:
inclusion criteria: * age \>18 years * meet criteria for pts or * patients with may thurner syndrome on additional imaging * life expectancy of more than one year * deep venous thrombosis \> 1 year * signed informed consent exclusion criteria: * previous intervention of central veins (inferior vena cava, iliac veins, common femoral vein) on the affected limb * known pregnancy * inability to answer dutch qol questionnaires or limited communication in dutch (written and spoken) * contra-indication for prolonged anticoagulant treatment * recent, \<1 year, deep venous thrombosis or pulmonary embolism * known contrast allergy * known dialysis or renal insufficiency needing additional preparation for injection of contrast
an observational study of avastin (bevacizumab) in patients with metastatic colorectal cancer (relevant)

Conditions: Colorectal Cancer

Summary: this prospective observational study will evaluate the safety and efficacy of avastin (bevacizumab) in patients with metastatic colorectal cancer. data will be collected from patients receiving avastin in combination with chemotherapy according to registered indication in routine clinical practice.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * metastatic colorectal cancer * prescribed to receive avastin according to registered indication exclusion criteria: * patients not eligible for avastin treatment according to the summary of product characteristics
the effect of obesity in copd mechanically ventilated patients

Conditions: Effects of Obesity on COPD Mechanically Ventilated Patients

Summary: study the relationship between the body mass index and duration of mechanical ventilation \& complications in mechanically ventilated copd patients. study the effect of obesity on mortality rate of copd mechanically ventilated patients. determine prevalence of obesity in mechanically ventilated copd patients.

obesity has become a global epidemic with prevalence rising both in developed and developing countries. the percentage of patients with obesity in the intensive care unit (icu) can be expected to increase concomitantly or even more since obesity increases the risk for a more severe disease course with more need for icu admission and mechanical ventilation . obesity, especially abdominal obesity (android fat distribution) and severe obesity, results in altered respiratory anatomy and physiology and, therefore, complicated airway management and adapted ventilator settings during mechanical ventilation. obesity appears to be associated with an increased risk of acute respiratory distress syndrome (ards) and infection, mainly pneumonia probably related to an imbalanced production of adipokines. in ventilated patients, obesity increases icu length of stay and the duration of mechanical ventilation . obesity is relatively common among individuals with copd, corresponding to 20%-35% of patients with copd. increasing evidence suggests that obesity is a risk factor for impaired quality of life, exercise intolerance, and suboptimal disease control in copd .

Eligibility criteria:
inclusion criteria: * adult patients of both genders more than 18 years old admitted at ricu, diagnosed copd and need mechanical ventilation from august 2023 to august 2024. exclusion criteria: patients less than 18 years old. patients who refused to participate in the research. patients with missing data.
e-learning+ rehab therapy

Conditions: Stroke

Summary: stroke survivors with arm paresis because of stroke use their "good" arm for daily activities, but in doing so may be self-limiting their own recovery of the "bad" arm. traditional models of stroke rehabilitation fail to fully engage the survivor and care partner(s) in actively planning post-discharge habits that improve their capacity to live well over their entire lives. this study will test a cutting-edge in-person therapy + online training program designed to progressively transfer the responsibility of driving post-stroke recovery from the therapist to the survivor.


Eligibility criteria:
inclusion criteria: * paresis of one arm/hand because of ischemic or hemorrhagic stroke \>2 mo. and \<3 yrs prior * moderate arm impairment defined as a baseline fugl-meyer assessment of the upper extremity score of at least 32±2 points but no more than 47±2 points (out of 60 points) * montreal cognitive assessment score ≥22 * ability to read english * ability to communicate as per the therapists' judgement at baseline testing * 21-90 years of age * wi-fi connection in the home and either a computer, smartphone or tablet. exclusion criteria: * lesion or injury to brainstem or cerebellum * other neurological disease that may impair motor or learning skills (e.g., parkinson's disease); * pain interfering with reaching * uncorrected vision making it difficult to read information on a computer, tablet or phone.
efficacy of surgical systems in combination with phacoemulsification: a retrospective analysis

Conditions: Open-Angle Glaucoma

Summary: real-world efficacy of hydrus microstent with omni surgical system in combination with phacoemulsification: a retrospective analysis

the use of combination phacoemulsification, omni canaloplasty and hydrus microstent successfully lowers iop in ethnically-diverse patients with open angle glaucoma

Eligibility criteria:
inclusion criteria: * subjects with h/o ceiol/omni/hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data * have glaucoma exclusion criteria: * patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * patients with refractory cme or cme persisting 3 months or more post-operatively * patients with incomplete iop, medication logs or vf data within post-operative period * prior incisional surgery or migs

Keywords: hydrus microstent omni surgical system phacoemulsification
development and validation of a language screening test in acute right hemispheric strokes

Conditions: Stroke

Summary: this is a bi-centric study whose main objective is the validation of a rapid screening test for language disorders in the acute phase of right hemisphere stroke. primary objective the main objective is the validation of a rapid language disorder screening tool that will be used in the acute phase of right hemispheric stroke. secondary objectives secondary objectives are: * characterize the "atypical crossed aphasia" since the acute phase of stroke with a large cohort of patients , which, to our knowledge, has never been done. * re-evaluate the number of patients with acute language disorder in right hemisphere stroke. * validate the use of r-last by different categories of carers

the r-last (right language screening test) comprises 8 subtests and a total of 15 items. validation will focus on the internal validity (no ceiling or floor effect, no redundancy, internal consistency), the external validity (against a "gold standard" in order to evaluate its specificity and its sensitivity) and the interclass agreement of r-last. the median time to administrate de scale will be calculated. the investigators will validate the scale by administering it to 300 consecutive patients within 24 hours after admission to our 2 stroke units (centre hospitalier de versailles and centre hospitalier du sud francilien) and to 100 stabilized patients with and without atypical crossed aphasia using the mec-p evaluation as a reference. patients must be 100% right-handed (edinburgh test), be of french mother tongue, have no history of neurological disease, have no sensory disturbances (blindness, deafness) and no mirror crossed aphasia detected by the last (minimum score of 14/15 with a loss point granted for the "automatic speech" subtest, potentially stranded in right strokes)

Eligibility criteria:
inclusion criteria: * patients must be the age of majority * patients with right hemispheric stroke in the acute phase (internal validation + inter-examiner validation) or stabilization phase (external validation) confirmed by mri or ct when mri contraindicated * patient with no "mirror" crossed aphasia detected by the last procedure (a or b): last\> 14 * patients who read the newsletter * affiliation to a social security scheme criteria exclusion: * minor patients * no french speakers * patients with a history of stroke * patients with dementia * patients with sensory impairment: deafness, blindness * patient not 100% right handed in the edinburgh questionnaire * inability to answer the edinburgh laterality questionnaire and absence of any person to fill in the questionnaire. * patient with a left-handed person in its family * illiterate patients * patient presenting a "mirror" crossed aphasia detected by last a or b (score tolerated: 14/15 with error accepted to the automatic speech) * inability to receive the information letter about the protocol and to read the newsletter * refusal of the patient

Keywords: right hemispheric stroke crossed aphasia acute phase